MO

Moderna

MRNA
NASDAQHealth Care

Insider Trades

mrna
2 months ago

Shannon Thyme Klinger sold 13,885 shares of MRNA on 2 March. They now own 59,689 MRNA shares, or a 19% holding decrease.

Shannon Thyme Klinger sold MRNA
mrna
2 months ago

Stephen Hoge sold 160,009 shares of MRNA on 23 February. They now own 1,457,427 MRNA shares, or a 10% holding decrease.

Stephen Hoge sold MRNA
mrna
5 months ago

Noubar Afeyan sold 23,853 shares of MRNA on 11 December. They now own 3,924 MRNA shares, or a 86% holding decrease.

Noubar Afeyan sold MRNA
mrna
5 months ago

Abbas Hussain sold 504 shares of MRNA on 9 December. They now own 1,515 MRNA shares, or a 25% holding decrease.

Abbas Hussain sold MRNA
mrna
11 months ago

Abbas Hussain sold 312 shares of MRNA on 11 June. They now own 580 MRNA shares, or a 35% holding decrease.

Abbas Hussain sold MRNA
mrna
1 year ago

Paul Sagan bought 31,620 shares of MRNA on 3 March. They now own 312,027 MRNA shares, or a 11% holding increase.

Paul Sagan bought MRNA
mrna
over 1 year ago

James M Mock sold 715 shares of MRNA on 7 October. They now own 9,505 MRNA shares, or a 7% holding decrease.

James M Mock sold MRNA
mrna
over 1 year ago

James M Mock sold 1,321 shares of MRNA on 28 August. They now own 8,600 MRNA shares, or a 13% holding decrease.

James M Mock sold MRNA
mrna
over 1 year ago

Shannon Thyme Klinger sold 1,319 shares of MRNA on 28 August. They now own 17,280 MRNA shares, or a 7% holding decrease.

Shannon Thyme Klinger sold MRNA
mrna
almost 2 years ago

James M Mock sold 689 shares of MRNA on 8 July. They now own 7,269 MRNA shares, or a 9% holding decrease.

James M Mock sold MRNA
mrna
almost 2 years ago

Noubar Afeyan sold 202,832 shares of MRNA on 11 June. They now own 1,528,557 MRNA shares, or a 12% holding decrease.

Noubar Afeyan sold MRNA
mrna
almost 2 years ago

Shannon Thyme Klinger sold 5,178 shares of MRNA on 10 June. They now own 15,947 MRNA shares, or a 25% holding decrease.

Shannon Thyme Klinger sold MRNA
mrna
almost 2 years ago

James M Mock sold 691 shares of MRNA on 3 June. They now own 6,506 MRNA shares, or a 10% holding decrease.

James M Mock sold MRNA
mrna
almost 2 years ago

Shannon Thyme Klinger sold 1,296 shares of MRNA on 28 May. They now own 10,623 MRNA shares, or a 11% holding decrease.

Shannon Thyme Klinger sold MRNA
mrna
almost 2 years ago

James M Mock sold 648 shares of MRNA on 28 May. They now own 5,726 MRNA shares, or a 10% holding decrease.

James M Mock sold MRNA
mrna
2 years ago

James M Mock sold 705 shares of MRNA on 8 April. They now own 5,048 MRNA shares, or a 12% holding decrease.

James M Mock sold MRNA
mrna
2 years ago

Noubar Afeyan sold 15,000 shares of MRNA on 20 March. They now own 2,116,931 MRNA shares, or a 1% holding decrease.

Noubar Afeyan sold MRNA
mrna
2 years ago

Noubar Afeyan sold 15,000 shares of MRNA on 13 March. They now own 2,131,931 MRNA shares, or a 1% holding decrease.

Noubar Afeyan sold MRNA
mrna
2 years ago

Shannon Thyme Klinger sold 544 shares of MRNA on 8 March. They now own 9,267 MRNA shares, or a 6% holding decrease.

Shannon Thyme Klinger sold MRNA
mrna
2 years ago

Stephen Hoge sold 309 shares of MRNA on 4 March. They now own 1,516,241 MRNA shares, or a 0% holding decrease.

Stephen Hoge sold MRNA
mrna
2 years ago

Shannon Thyme Klinger sold 117 shares of MRNA on 4 March. They now own 8,673 MRNA shares, or a 1% holding decrease.

Shannon Thyme Klinger sold MRNA
Cashu Markets
Cashu
Markets

By Cashu Markets. Providing market news, analysis, and research for investors worldwide.

© 2026 Cashu Technologies Pty Ltd. All rights reserved. Cashu Markets is a trademark of Cashu Technologies Pty Ltd.

The content published on Cashu Markets is for informational purposes only and should not be construed as investment advice, a recommendation, or an offer to buy or sell any securities. All opinions expressed are those of the authors and do not reflect the official position of Cashu Technologies Pty Ltd or its affiliates. Past performance is not indicative of future results. Investing involves risk, including the possible loss of principal. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Cashu Markets and its contributors may hold positions in securities mentioned in published content. Any such holdings will be disclosed at the time of publication. Market data is provided on an "as-is" basis and may be delayed. Cashu Technologies Pty Ltd does not guarantee the accuracy, completeness, or timeliness of any information presented.

Cashu Markets
Cashu
Markets

Setting up your session...